☆ 4.7 Article

A Quantitative Systems Pharmacology Model of Liver Lipid Metabolism for Investigation of Non-Alcoholic Fatty Liver Disease

FRONTIERS IN PHARMACOLOGY (2022)

Related references

Note: Only part of the references are listed.

Review Chemistry, Multidisciplinary

Applications of Quantitative Systems Pharmacology (QSP) in Drug Development for NAFLD and NASH and Its Regulatory Application

Scott Q. Siler

Summary: Nonalcoholic steatohepatitis (NASH) is a prevalent disease without approved pharmaceutical treatments. Quantitative systems pharmacology (QSP) can improve drug development in this area by modeling disease pathophysiology and pharmacological interventions. Several QSP models have been developed for NASH. Simulations using QSP model NAFLDsym showed the impact of patient behaviors on fibrosis stage reductions.

PHARMACEUTICAL RESEARCH (2022)

Add to Collection

Article Biochemistry & Molecular Biology

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

Roberto A. Calle et al.

Summary: The study showed that ACC1/2 inhibitors had a good therapeutic effect in the treatment of non-alcoholic fatty liver disease, significantly reducing liver fat content. Co-administration of PF-05221304 and PF-06865571 can reduce the incidence of adverse events and mitigate the effect of ACC inhibition on serum triglycerides.

NATURE MEDICINE (2021)

Add to Collection

Article Cell Biology

Computational Hypothesis: How Intra-Hepatic Functional Heterogeneity May Influence the Cascading Progression of Free Fatty Acid-Induced Non-Alcoholic Fatty Liver Disease (NAFLD)

Hermann-Georg Holzhuetter et al.

Summary: Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common type of chronic liver disease in developed nations, affecting around 25% of the population. Intra-hepatic heterogeneity of rheological, metabolic and tissue-regenerating capacities has been found to play a central role in disease progression. Model simulations indicate that a persistently high plasma level of FFAs can drive the liver through different stages of NAFLD, with the presence of NAFLD amplifying the impact of additional tissue-damaging hits and the coexistence of non-steatotic and highly steatotic regions being indicative for the later occurrence of severe NAFLD stages.

CELLS (2021)

Add to Collection

Article Medicine, General & Internal

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome et al.

Summary: This phase 2 trial demonstrated that treatment with semaglutide resulted in a significantly higher percentage of patients with NASH resolution compared to placebo in patients with NASH, but did not show a significant between-group difference in the percentage of patients with an improvement in fibrosis stage.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Gastroenterology & Hepatology

PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH

Amalia Gastaldelli et al.

Summary: The study found that PPAR-gamma agonists, along with an increase in ADPN levels, a decrease in VF, and an improvement in VF/SC fat distribution, are closely related to improving the pathological condition of patients with NASH.

LIVER INTERNATIONAL (2021)

Add to Collection

Article Pharmacology & Pharmacy

A Prototype QSP Model of the Immune Response to SARS-CoV-2 for Community Development

Wei Dai et al.

Summary: The text discusses the importance of developing effective treatments for COVID-19 caused by the SARS-CoV-2 pandemic, introduces quantitative systems pharmacology models and their applications, and presents a prototype model for further development. The model captures two physiological outcomes post-infection and aims to accelerate QSP model development by encouraging community use and refinement.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview

Gopanandan Parthasarathy et al.

HEPATOLOGY COMMUNICATIONS (2020)

Add to Collection

Review Gastroenterology & Hepatology

Epidemiology of non-alcoholic and alcoholic fatty liver diseases

Souveek Mitra et al.

TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2020)

Add to Collection

Article Mathematical & Computational Biology

Analysis of compartments-in-series models of liver metabolism as partial differential equations: the effect of dispersion and number of compartments

Marcella Noorman et al.

MATHEMATICAL BIOSCIENCES AND ENGINEERING (2019)

Add to Collection

Article Gastroenterology & Hepatology

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Naga Chalasani et al.

HEPATOLOGY (2018)

Add to Collection

Article Endocrinology & Metabolism

A mathematical analysis of adaptations to the metabolic fate of fructose in essential fructosuria subjects

Richard J. Allen et al.

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2018)

Add to Collection

Review Gastroenterology & Hepatology

Lipotoxicity and the gut-liver axis in NASH pathogenesis

Fabio Marra et al.

JOURNAL OF HEPATOLOGY (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Improving the generation and selection of virtual populations in quantitative systems pharmacology models

Theodore R. Rieger et al.

PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY (2018)

Add to Collection

Article Mathematics, Applied

Julia: A Fresh Approach to Numerical Computing

Jeff Bezanson et al.

SIAM REVIEW (2017)

Add to Collection

Article Pharmacology & Pharmacy

Benefits and challenges of a QSP approach through case study: Evaluation of a hypothetical GLP-1/GIP dual agonist therapy

Theodore R. Rieger et al.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)

Add to Collection

Article Gastroenterology & Hepatology

Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes

Zobair M. Younossi et al.

HEPATOLOGY (2016)

Add to Collection

Article Endocrinology & Metabolism

Long-Lasting Improvements in Liver Fat and Metabolism Despite Body Weight Regain After Dietary Weight Loss

Sven Haufe et al.

DIABETES CARE (2013)

Add to Collection

Article Endocrinology & Metabolism

Predicting metabolic adaptation, body weight change, and energy intake in humans

Kevin D. Hall

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)

Add to Collection

Review Endocrinology & Metabolism

Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c

P. Ferre et al.

DIABETES OBESITY & METABOLISM (2010)

Add to Collection

Article Gastroenterology & Hepatology

Importance of Changes in Adipose Tissue Insulin Resistance to Histological Response During Thiazolidinedione Treatment of Patients with Nonalcoholic Steatohepatitis

Amalia Gastaldelli et al.

HEPATOLOGY (2009)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Pioglitazone: More than Just an Insulin Sensitizer

Mark J. Czaja

HEPATOLOGY (2009)

Add to Collection

Article Endocrinology & Metabolism

Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study

Giuseppe Derosa et al.

METABOLISM-CLINICAL AND EXPERIMENTAL (2009)

Add to Collection

Review Hematology

Fatty liver - A novel component of the metabolic syndrome

Anna Kotronen et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)

Add to Collection

Article Endocrinology & Metabolism

Liver fat in the metabolic syndrome

Anna Kotronen et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)

Add to Collection

Article Medicine, General & Internal

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

Renata Belfort et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Add to Collection

Article Medicine, General & Internal

Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA1c:: a meta-analysis of published randomized clinical trials

Hemant M. Phatak et al.

CURRENT MEDICAL RESEARCH AND OPINION (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.